These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12147177)

  • 1. Antitubercular therapy decreases nitric oxide production in HIV/TB coinfected patients.
    Wanchu A; Bhatnagar A; Khullar M; Sud A; Bambery P; Singh S
    BMC Infect Dis; 2002 Jul; 2():15. PubMed ID: 12147177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count.
    Mahan CS; Walusimbi M; Johnson DF; Lancioni C; Charlebois E; Baseke J; Chervenak KA; Mugerwa RD; Havlir DV; Mayanja-Kizza H; Whalen CC; Boom WH;
    PLoS One; 2010 Feb; 5(2):e9138. PubMed ID: 20179751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Levels of Neopterin and C-Reactive Protein (CRP) in Tuberculosis (TB) with and without HIV Coinfection in Relation to CD4 Cell Count.
    Skogmar S; Schön T; Balcha TT; Sturegård E; Jansson M; Björkman P
    PLoS One; 2015; 10(12):e0144292. PubMed ID: 26630153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.
    Antwi S; Yang H; Enimil A; Sarfo AM; Gillani FS; Ansong D; Dompreh A; Orstin A; Opoku T; Bosomtwe D; Wiesner L; Norman J; Peloquin CA; Kwara A
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of tuberculosis treatment on CD4 cell count, HIV RNA, and p24 antigen in patients with HIV and tuberculosis.
    Wejse C; Furtado A; Camara C; Lüneborg-Nielsen M; Sodemann M; Gerstoft J; Katzenstein TL
    Int J Infect Dis; 2013 Oct; 17(10):e907-12. PubMed ID: 23816410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C Virus Affects Tuberculosis-Specific T Cells in HIV-Negative Patients.
    El-Mokhtar MA; Elgendy SG; Eldin AS; Hassan EA; Hasan AAA; Abdel Hameed MR; Sayed D; Salama EH
    Viruses; 2020 Jan; 12(1):. PubMed ID: 31952232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pentoxiphylline reduces nitric oxide production among patients with HIV infection.
    Wanchu A; Khullar M; Bhatnagar A; Sud A; Bambery P; Singh S
    Immunol Lett; 2000 Oct; 74(2):121-5. PubMed ID: 10996387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old.
    Kwara A; Yang H; Antwi S; Enimil A; Gillani FS; Dompreh A; Ortsin A; Opoku T; Bosomtwe D; Sarfo A; Wiesner L; Norman J; Alghamdi WA; Langaee T; Peloquin CA; Court MH; Greenblatt DJ
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial extensively drug-resistant tuberculosis in an HIV-infected child: a case report and review of literature.
    Uppuluri R; Shah I
    J Int Assoc Provid AIDS Care; 2014; 13(2):117-9. PubMed ID: 24401768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study.
    Sekaggya-Wiltshire C; Castelnuovo B; von Braun A; Musaazi J; Muller D; Buzibye A; Gutteck U; Henning L; Ledergerber B; Corti N; Lamorde M; Fehr J; Kambugu A
    BMJ Open; 2017 Sep; 7(9):e014679. PubMed ID: 28928173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia.
    Mwinga A; Hosp M; Godfrey-Faussett P; Quigley M; Mwaba P; Mugala BN; Nyirenda O; Luo N; Pobee J; Elliott AM; McAdam KP; Porter JD
    AIDS; 1998 Dec; 12(18):2447-57. PubMed ID: 9875583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
    Chideya S; Winston CA; Peloquin CA; Bradford WZ; Hopewell PC; Wells CD; Reingold AL; Kenyon TA; Moeti TL; Tappero JW
    Clin Infect Dis; 2009 Jun; 48(12):1685-94. PubMed ID: 19432554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
    van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus infection in children with tuberculosis in Santo Domingo, Dominican Republic: prevalence, clinical findings, and response to antituberculosis treatment.
    Espinal MA; Reingold AL; Pérez G; Camilo E; Soto S; Cruz E; Matos N; Gonzalez G
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Oct; 13(2):155-9. PubMed ID: 8862280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disseminated infection due to multidrug-resistant Mycobacterium bovis in a patient who was seropositive for human immunodeficiency virus.
    Schultsz C; Kuijper EJ; van Soolingen D; Prins JM
    Clin Infect Dis; 1996 Oct; 23(4):841-3. PubMed ID: 8909864
    [No Abstract]   [Full Text] [Related]  

  • 16. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.
    Li J; Munsiff SS; Driver CR; Sackoff J
    Clin Infect Dis; 2005 Jul; 41(1):83-91. PubMed ID: 15937767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
    Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
    Chirehwa MT; McIlleron H; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; Denti P
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1.
    Patel A; Patel K; Patel J; Shah N; Patel B; Rani S
    J Acquir Immune Defic Syndr; 2004 Sep; 37(1):1166-9. PubMed ID: 15319677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incomplete immunological recovery following anti-tuberculosis treatment in HIV-infected individuals with active tuberculosis.
    Hanna LE; Nayak K; Subramanyam S; Venkatesan P; Narayanan PR; Swaminathan S
    Indian J Med Res; 2009 May; 129(5):548-54. PubMed ID: 19675383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.